Precision Optics Corporation, Inc. — Form 10-Q Summary
Reporting period: The filing covers the fiscal third quarter and first nine months ended March 31, 2013. Although the request metadata says “2012 Q3,” the filing itself reports fiscal 2013 Q3 results.
Business context
The company designs and manufactures medical optical instruments, including endoscopes, micro-optics and imaging systems; approximately 10% of its business is military and industrial products. It is pursuing commercialization of Microprecision optical technology and next-generation 3D endoscopes.
Financial results
| Metric | Three months ended March 31, 2013 | Three months ended March 31, 2012 | Nine months ended March 31, 2013 | Nine months ended March 31, 2012 |
|---|---|---|---|---|
| Revenue | $655,341 | $382,264 | $1,717,406 | $1,380,787 |
| Gross profit (margin) | $158,761 (24.2%) | $10,323 (2.7%) | $368,572 (21.5%) | $260,937 (18.9%) |
| Operating loss | $(349,994) | $(490,890) | $(1,060,313) | $(1,066,435) |
| Net income (loss) | $(349,994) | $(492,139) | $(1,614,572) | $1,181,427 |
- Quarterly revenue rose 71.4% year over year and 31.4% sequentially; nine-month revenue increased 24.4%. Management attributed growth mainly to higher sales volume of a surgical visualization system, partly offset by lower sales of endoscopes, endocouplers and micro-optics.
- Quarterly gross margin improved substantially, primarily with higher overall unit volume; management also cited product mix, consulting expenses and nonrecurring manufacturing startup costs as factors affecting margins.
- The nine-month net loss contrasts with prior-year net income, which included a $2.276 million gain on patent sales. Current-period results included a $629,000 noncash provision for settlements of registration-rights claims.
- Research and development expense was $159,472 for the quarter and $533,424 for nine months. Selling, general and administrative expense was $350,180 and $900,060, respectively.
Cash, liquidity and debt
- At March 31, 2013, cash and cash equivalents were $1,278,384, versus $145,923 at June 30, 2012; current assets were $2,476,988 and current liabilities $657,921.
- Operating activities used $1,057,207 in cash during the nine months. The company reported $343,539 of operating cash use in the March quarter, an improvement from $485,542 in the December quarter.
- Financing activities provided $2,188,619 in the nine months, chiefly from the September 2012 equity and warrant offering. Investing activities provided $1,049.
- The 10% senior secured convertible notes were fully repaid in September 2012; no note balance remained at March 31, 2013. The filing states the company was not in default on indebtedness.
- Contractual commitments included approximately $35,149 of operating lease payments and approximately $186,000 in open purchase orders as of March 31, 2013.
Outlook, risks and unusual items
- No quantified revenue or earnings guidance is provided. Management expects operating losses to continue until sales reach breakeven and profitable levels, while expressing confidence that new products and orders may support future revenue growth.
- Management reported a $660,000 follow-on custom-endoscope order scheduled for manufacture and delivery over 16 months beginning July 2013, an earlier $1.032 million endoscope order, and an approximately $250,000 micro-camera assembly order. Shipments against certain new-product orders were expected to begin in the coming months; timing and revenue growth remain uncertain.
- Customer concentration is significant: one customer represented 55% of nine-month revenue, compared with 15% in the prior-year period. Management noted that order timing can cause concentration to fluctuate.
- A September 2012 private placement raised $2.5 million gross through common stock and warrants. The issuance increased shares outstanding and triggered anti-dilution adjustments to certain older warrants. Management also said the placement may limit the use of tax-loss carryforwards.
- Special Situations’ demand for $719,100 in liquidated damages was settled without cash payment through issuance of 350,000 shares and 350,000 warrants, plus an extension of certain warrant expirations. Separate settlements with two other stockholders also involved share and warrant issuances. A different stockholder demanded rescission or $179,316; the company said no lawsuit had been filed and it considered the claims without merit.
- Disclosure controls and internal control over financial reporting were reported ineffective at March 31, 2013. Management identified material weaknesses relating to segregation of accounting duties and inventory valuation, and said remediation efforts were ongoing.
- Other business risks include lengthy product development and regulatory processes, competition in a price-driven market, continuing operating losses, and uncertainty in customer order timing. The filing reported no material changes to the risk factors in the prior annual report.
Most important facts to verify
- Whether expected production and deliveries for the disclosed endoscope and micro-camera orders occurred on schedule and generated the anticipated revenue and margins.
- Whether the company can reduce operating cash use and reach breakeven before its available cash is depleted.
- How the 55% revenue concentration in one customer changes, and whether new customers and products diversify sales.
- Progress in remediating the reported material weaknesses in financial reporting controls, particularly inventory valuation and segregation of duties.
- Any developments in the stockholder demand and the financial or dilution effects of settlement securities and outstanding warrants.